BackU-Neuron Biomedical Overview

U-Neuron Biomedical EBIT

U-Neuron Biomedical's EBIT is $-120M, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$33.08M
↓ 42.7% YoY

As of Jun 30, 2026

Annual EBIT (TTM)

-$120.61M

Trailing 12 months ending Jun 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

U-Neuron Biomedical (6973.TWO) FAQ

As of the most recent data (June 2026), 6973.TWO shows a EBIT of $-120M. That is below the Healthcare sector average of $1.9T. Scroll down for historical charts and peer comparison views.

The Healthcare sector average EBIT is about $1.9T. U-Neuron Biomedical is at $-120M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how 6973.TWO stacks up against individual peers as well.

Tracking 6973.TWO's ebit over time shows whether U-Neuron Biomedical is scaling, shrinking, or reshaping that part of the business. The current reading is $-120M Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has U-Neuron Biomedical's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-120M) with ownership activity and broader fundamentals.

The Healthcare average EBIT is about $1.9T, while 6973.TWO is at $-120M. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.